From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

NMRC Provides Ebola Assays for W. Africa

by Global Biodefense Staff
October 22, 2014
NMRC Researcher Creating Ebola Reagents

After a large batch of Ebola specific PCR master mix is produced, the mix is aliquoted into individual tubes (NMRC)

The Naval Medical Research Center (NMRC) has been supporting DoD’s interagency efforts since the early months of the Ebola outbreak, which began in December 2013, when initial cases were reported in Guinea and later spread to Sierra Leone and Liberia.

A research team from NMRC’s Biological Defense Research Directorate (BDRD) has been busy producing more than 100,000 Ebola detection assays for the Medical Countermeasure System’s Critical Reagents Program (CRP), a part of the DoD Joint Project Management Office.

“We were tasked to produce assays when the outbreak began and as the crisis continues to worsen, our production tempo has increased dramatically. Our team is producing these assays every day,” said Dr. Joan Gebhardt, head of Molecular Diagnostics at BDRD.

Providing Important Biothreat Reagents

As part of its mission, BDRD produces reagents and detection assays for research and development in the DoD, U.S. agencies and other partners. These Ebola-specific assays are used in West Africa. Blood samples are being collected from patients exhibiting symptoms and tested to detect infection. These assays are used to confirm patients with probable or suspected Ebola virus disease so they can be moved to treatment centers; the assays are also used for screening potential contacts of infected individuals.

“This effort is a great example of what BDRD is capable of, quick rapid turnaround to provide detection assays for emerging infectious diseases anywhere on the globe,” said Cmdr. Guillermo Pimentel, Deputy Director of BDRD.

According to the Centers for Disease Control and Prevention‘s (CDC) website the first Ebola virus species was discovered in 1976 in what is now the Democratic Republic of the Congo near the Ebola River.

Since then, outbreaks have appeared sporadically. Ebola virus disease is characterized by fever, severe diarrhea, vomiting and can present as a severe viral hemorrhagic fever, an often fatal disease.

The disease is often spread through families and friends because they come in close contact when caring for ill persons. The disease can also spread quickly within clinics or hospitals in resource poor settings with limited infection control capabilities.

A Key Role in Protecting Military & Civilian Personnel

BDRD is focused on research and development to protect U.S. military personnel and civilians from the threat of infectious diseases and biological attacks.

The lab is certified as a National Laboratory within the CDC’s Laboratory Response Network for biological hazard testing and analysis. In addition, the production labs for molecular and immunological assays are under International Organization for Standardization ISO Guide 34/17025 accreditation.

The research team supports Naval Sea Systems Command ensuring Fleet protection, outfitting the Navy and Marine Corps with bioweapons defense field testing capabilities and managing the proficiency testing program for the Joint Biological Agent and Identification and Detection System platform.

Supporting the U.S. Government Health Security Agenda, the laboratory continues to expand their international research collaborations and programs.

Article and image courtesy of Naval Medical Research Center Public Affairs, edited for context and format.

From Our Partners
Tags: Ebola

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
Health Security

Resurgent COVID-19, Flu and Other Viruses are Pushing New Zealand’s Health System to the Limit

June 2, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC